Content
12/06/2024
Menlo Park, CA USA
Nuvig Therapeutics
completed $161 million Series B Round funding. Investors include
Blue Owl Capital (lead), Sanofi Ventures (lead), Norwest Venture Partners (lead), Global BioAccess Fund, Digitalis Ventures, Leaps by Bayer, Novo Holdings, B Capital, Alexandria Venture Investments, Bristol Myers Squibb, abrdn, Mission BioCapital.
About
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
